Pivotal Therapeutics reports third quarter 2012 financial results
WOODBRIDGE, ON, Nov. 29, 2012 /PRNewswire/ – Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular
disease and overall health today announced its financial results and
operational highlights for the quarter ended September 30, 2012. All
dollar amounts referenced herein are in Canadian dollars unless
For the three months ended September 30, 2012 the Company reported a
loss of $811,164, or $0.01 per common share, compared with a loss of
$591,022 or $0.01 per common share for the three months ended September
30, 2011. At September 30, 2012, Pivotal’s current assets totaled
$1,274,508 compared with $2,215,820 at December 31, 2011. The decrease
in current assets during the nine months ended September 30, 2012, is
primarily due to a reduction in cash utilized in the expansion of sales
and marketing of our lead product VASCAZEN(®).
“Subsequent to the end of the third quarter Pivotal received additional
funding from its private placement and Crossover Healthcare Fund
remains committed to and will continue to fund the company in tranches
at the original terms of the agreement until the round of financing is
complete,” stated Eugene Bortoluzzi, Chief Executive Officer and Chief
Highlights for 2012:
-- April 3, 2012 - the Company began trading in the U.S. on the OTC Markets' QX Marketplace, under the symbol PVTTF; -- April 30, 2012 - the Company announced its 2011 financial results; -- May 22, 2012 - the Company announced first prescription sales in the U.S.; -- May 28, 2012 - the Company announced its Q1 financial results; -- June 25, 2012 - the Company announced U.S. Institutional Private Placement for $5M CDN; -- August 9, 2012 - the Company announced that data from a scientific study, presented at the 17th World Congress On Heart Disease demonstrated the superiority of VASCAZEN®'s unique formulation; -- August 23, 2012 - the Company announced that further data presented at the European Society of Cardiology Congress, demonstrated the superiority of VASCAZEN®'s unique formulation; -- August 28, 2012 - the Company announced its Q3 financial results; -- August 23, 2012-the Company announced it generated positive feedback at the European Society of Cardiology Congress -- September 6, 2012-the Company announced a presentation at the Rodman & Renshaw 14th Annual Healthcare Conference -- October 9, 2012-the Company announced it exhibited at the 2012 Cardiometabolic Health Congress -- October 29, 2012-the Company announced it filed amended 2012 Q1 and Q2 financial statements to more fully comply with IFRS disclosure requirements. -- November 5, 2012- the Company announced it exhibited at the American Heart Associations (AHA) Scientific Sessions.
Pivotal’s Goals for 2012:
-- Advance commercialization of VASCAZEN®in the U.S.; -- Expansion of the sales & marketing team; -- Initiation of new clinical trials; -- Completion of existing clinical trials for VASCAZEN®and publication of scientific data; -- Expansion of intellectual property portfolio; -- Investigation of international licensing opportunities; -- Expansion of product offerings; -- Investment community presentations to increase awareness; -- Presentations and attendance at scientific meetings.
The unaudited consolidated financial statements, accompanying notes and
Management’s Discussion and Analysis for the three and nine months
ended September 30, 2012, are accessible on Pivotal’s website at www.pivotaltherapeutics.us and on SEDAR (www.sedar.com).
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health. Pivotal Therapeutics’ lead product VASCAZEN(®) is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.
VASCAZEN(®) is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending US and foreign patents and
commercialized as a prescription only Medical Food. This unique
formulation will provide the cornerstone upon which a family of cutting
edge combination products, with efficacy across a broad spectrum of
cardiac care, will be commercialized.
OMAZEN(TM) is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality
The information contained in this document is as of November 29, 2012.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal’s actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as “will”, “anticipate”, “estimate”, “expect”, “project”, “forecast”,
“intend”, “plan”, “believe”, “project”, “potential”, and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal’s inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company’s products will not gain widespread market acceptance; risks
relating to the Company’s ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.